Heron Therapeutics outlines $153M–$163M net revenue target as acute care momentum accelerates

Q3 2025 Management View CEO Craig Collard opened with the announcement of successful completion of financing, stating: "This ...

Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -150.00% and -0.91%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the ...

Heron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Tuesday, ...
The Bakersfield Californian

Heron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial Progress

Generated Q3 2025 Net Revenue of $38.2 million and year-to-date revenue of $114.3 million; reaffirmed 2025 Net Revenue Guidance of $153 million - $163 million and adjusted EBITDA of$9.0 - ...
TipRanks on MSN

Heron Therapeutics Appoints Thomas Cusack to Board

Heron Therapeutics ( ($HRTX) ) has issued an update. On October 27, 2025, Heron Therapeutics appointed Thomas Cusack to its Board of Directors, ...